NASDAQ:TREE
LendingTree Stock News
$45.06
+2.00 (+4.64%)
At Close: May 24, 2024
Time to Buy These 2 Financial Lending Stocks?
12:36am, Wednesday, 11'th Jan 2023 Zacks Investment Research
There could be huge upside potential for LendingTree and LendingClub and it may be time to look at these stocks while they are near multi-year lows.
Time to Buy These 2 Financial Lending Stocks?
09:04pm, Tuesday, 10'th Jan 2023
There could be huge upside potential for LendingTree and LendingClub and it may be time to look at these stocks while they are near multi-year lows.
Zacks Value Investor Highlights: Deutsche Bank, LendingTree, Phillips 66, PVH, Urban Outfitters
01:42pm, Monday, 09'th Jan 2023 Zacks Investment Research
Deutsche Bank, LendingTree, Phillips 66, PVH, Urban Outfitters have been highlighted in this Value Investor article.
5 Top Classic Value Stocks to Start 2023
07:09pm, Friday, 06'th Jan 2023 Zacks Investment Research
A low P/E isn't enough. These companies also have value PEG and P/S ratios along with the top Zacks Ranks.
Meet The 5 Unlucky Investors Who Loaded Up On Year's Worst Stocks
08:00am, Monday, 19'th Dec 2022
Few investors can hit all the year's best S&P 500 stocks. But some were unlucky enough to own big stakes of the worst.
7 Real Estate Stocks to Sell
06:00am, Monday, 21'st Nov 2022
As the housing downturn continues and looks poised to get worse, it remains best to approach real estate stocks cautiously. Admittedly, the shares of real estate investment trusts (or REITs) and the s
LendingTree, Inc. to Present at the Stephens Annual Investment Conference
12:15pm, Tuesday, 15'th Nov 2022
CHARLOTTE, N.C. , Nov. 15, 2022 /PRNewswire/ -- LendingTree, Inc. (NASDAQ: TREE), operator of LendingTree.com, the nation's leading online financial services marketplace, today announced that it will
LendingTree, Inc. (TREE) Q3 2022 Earnings Call Transcript
10:34pm, Thursday, 03'rd Nov 2022
LendingTree, Inc. (NASDAQ:TREE ) Q3 2022 Earnings Conference Call November 3, 2022 9:00 AM ET Company Participants Andrew Wessel - Head, IR Douglas Lebda - Chairman and CEO John Moriarty - COO and Pre
Tree.com (TREE) Reports Q3 Loss, Lags Revenue Estimates
09:47am, Thursday, 03'rd Nov 2022
Tree.com (TREE) delivered earnings and revenue surprises of 59.55% and 1.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sixth Street (TSLX) Misses Q3 Earnings Estimates
10:55pm, Tuesday, 01'st Nov 2022 Zacks Investment Research
Sixth St (TSLX) delivered earnings and revenue surprises of -4.08% and 1.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
7 Stocks to Buy if You Are Feeling Greedy
11:44am, Thursday, 13'th Oct 2022
Before you proceed any further, you should realize that these “stocks to buy” (and I'm putting the term inside quotation marks for a reason) represent incredible risks. Yeah, yeah, I know that War
Forget Gas Prices: Dating Is Why People Are Going Broke In 2022
07:18pm, Wednesday, 12'th Oct 2022 Benzinga
It’s not breaking news that gas prices, rent, food and virtually everything else are more expensive than it was just a year or two ago.
Despite some items getting less expensive, such as chicken w
The real challenge is how long these real estate market conditions last, says BofA's Bhatia
03:12pm, Monday, 19'th Sep 2022
Bank of America Securities research analyst Mihir Bhatia joins 'Power Lunch' to discuss how much mortgage volumes will fall, if Bhatia's coverage universe can survive a fall in mortgage volumes and wh
Why Amazon Shares Traded Lower; Here Are 74 Biggest Movers From Yesterday
10:11am, Tuesday, 23'rd Aug 2022 Benzinga
Gainers
Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 72.8% to close at $2.16 on Monday as the stock continued to see momentum despite the company last week announcing it is not aware of
Why MSP Recovery Is Trading Higher By Over 21%, Here Are 61 Stocks Moving In Monday's Mid-Day Session
05:02pm, Monday, 22'nd Aug 2022 Benzinga
Gainers
Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares surged 78% to $2.2399 as the stock continued to see momentum despite the company last week announcing it is not aware of any developments